Tags : 22F


Merck’s V114 Receives FDA’s Breakthrough Therapy Designation to Prevent Invasive

Shots: The BT designation is based on P-I/II and P-II results assessing four lots of V114 in healthy adults and infants, demonstrating non-inferiority data in patients FDA’s BT designation is granted to the drugs showing clinical improvement over a currently available therapy on at least one clinically significant endpoint with benefits of Priority Review and […]Read More